SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

SpaceXs agreement to acquire low-band spectrum for Starlink Mobile sparked a sharp selloff in T-Mobile and other wireless carriers as traders weighed the prospect of a new competitor. The community is divided between seeing a meaningful long-term threat and calling the reaction excessive because building a competitive network would take substantial time and investment.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

SpaceXs agreement to acquire low-band spectrum for Starlink Mobile has raised concerns about future competition for AT&T and weighed on telecom shares. Traders are divided between viewing the selloff as an overreactiongiven the years and infrastructure needed to build a rival networkand seeing the deal as a credible long-term threat; many are also buying the dip for AT&Ts dividend.

Verizon Communications, Inc. is a holding company, which engages in the provision of communications, information, and entertainment products and services. It operates through the following business segments: Consumer and Business. The Consumer segment provides consumer-focused wireless and wire line communications services and products. The Business segment offers wireless and wireline communications services and products, including FWA broadband, data, video and conferencing services, corporate networking solutions, security and managed network services, local and long-distance voice services, and network access to deliver various IoT services and products. The company was founded in 1983 and is headquartered in New York, NY.

Verizon Communications Inc

Verizon Communications Inc.

Verizons sharp selloff follows SpaceXs agreement to acquire low-band spectrum for Starlink Mobile, fueling concern that it could eventually compete for wireless customers. Traders are divided between viewing the deal as a long-term threat and calling the reaction excessive given the infrastructure and time needed to build a competing network; some see the drop as a buying opportunity based on Verizons dividend and cash flows.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

AXSM is drawing attention amid a steep, sustained share-price decline that investors say lacks a clear explanation, with frustration focused on managements limited communication. The debate centers on whether Auvelitys Alzheimers agitation launch is gaining traction: bulls cite rising prescriptions and possible data undercounting, while skeptics question whether uptake is accelerating enough to support growth and a path to profitability.

Listed Funds Trust - Roundhill Magnificent Seven ETF

Roundhill Magnificent Seven ETF

Renewed strength in the Magnificent Seven and reports of fresh highs have put MAGS in focus, with traders saying mega-cap tech is leading the market while smaller stocks lag. Optimists see leadership continuing, while skeptics point to narrow breadth and uncertain returns on AI spending as risks.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is rallying to fresh highs amid strength in software stocks, with traders highlighting its breakout and momentum. Bulls point to AI-related observability demand, while skeptics warn that the valuation is stretched and the move could reverse.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas Nasdaq-100 reentry and a reported NIH effort to accelerate personalized cancer vaccines have fueled buying, alongside optimism about its partnered mRNA melanoma-vaccine program with Merck. Traders are divided over whether index-related demand and cancer-vaccine hopes justify the sharp run, with skeptics pointing to valuation and ongoing losses and warning of a pullback.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML is drawing attention as traders position around its upcoming earnings report amid a busy semiconductor reporting cycle. Many expect AI-related chip demand to support the outlook, while others are cautious about a pullback or prefer to wait for the results.

Ginkgo Bioworks Holdings, Inc. engages in developing biological engineering products and custom microbes. Its platform enables biotechnology applications across diverse markets, from food, agriculture, industrial chemicals, and pharmaceuticals. It operates through the Cell Engineering and Biosecurity segments. The Cell Engineering segment includes end-to-end cell engineering solutions and cell engineering tools offerings for biological research and development. The Biosecurity segment focuses on biomonitoring and bioinformatics support services, offered to both government and non-government customers through its Canopy and Horizon offerings. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A

Ginkgos autonomous-lab push is drawing attention, including the Araceli imaging-system integration and lab access and protein-testing services for NSF X-Labs researchers. Bulls see potential in AI-driven biology infrastructure, while skeptics question whether the partnerships will translate into revenue amid cash-burn concerns and sharp share-price swings.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

A joint request to extend claim-construction briefing deadlines in Aurinias generic-voclosporin patent litigation has fueled speculation that settlements may be nearing, though none is confirmed. Traders welcomed the share-price rebound, while others expect it to fade and remain frustrated by continued delays and limited company updates.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Will Vertex's Kidney Disease Pipeline Be a New Growth Engine?

VRTX is expanding beyond its CF stronghold with a promising kidney disease pipeline led by povetacicept and inaxaplin.

Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch Next

Equity

Large-cap healthcare outperformed this week: XLV gained 1.4% through Tuesday, while XBI fell 1.4% and IBB declined 0.5%.

VERA Stock Jumps 16% Premarket – Trutakna Cuts Kidney Disease Progression Risk By 76%, Full FDA Filing Planned In Q4

Vera Therapeutics stated that Trutakna's commercial launch generated more than 350 patient start forms in the first 10 weeks.

Futures Drop As Yields, Oil Prices Keep Rising

Futures Drop As Yields, Oil Prices Keep Rising

 Futures are lower - but well off session lows thanks to some well-time oil sell orders just before US traders walked in to work - as bond yields continue to make new highs, with both Nasdaq and Russell lagging the S&P which feels like...

VERA’s TRUTAKNA Stuns in Two-Year Data and Full-Approval Jackpot Is Now in Sight

Vera Therapeutics (NASDAQ:VERA) has delivered the kind of clinical readout that can fundamentally change the investment narrative around a commercial-stage biotech: its TRUTAKNA (atacicept-vymj) program has produced two-year data showing stabilization of kidney function and a dramatic reduction in kidney disease progression in patients with IgA nephropathy (IgAN).

VERA Stock Surges After Drug To Treat Rare Kidney Disease Gets FDA Approval – Retail Sees The Move As Catalyst For Vera Therapeutics

Vera Therapeutics' Trutakna received an early, fast-tracked approval from the FDA to reduce proteinuria in adults with primary IgA Nephropathy whose health is at risk of deterioration. 


Why Is Vera Therapeutics Stock Gaining Tuesday?

Vera Therapeutics (VERA) stock jumps 9% following FDA accelerated approval for its kidney disease drug Trutakna. Full analysis here.read more...

VERA Stock Rallies Ahead Of High-Stakes FDA Decision On Lead Kidney Disease Drug – Retail Sees 35% Potential Upside

The U.S. Food and Drug Administration is set to announce its decision on Atacicept later on Monday, paving the way for the potential commercialization of the drug in the U.S.

Vera Therapeutics Moves Closer To Full Approval For Kidney Disease Drug After FDA Alignment

The biotech moves a step closer to full approval in IgAN as regulators agree to an accelerated timeline for key kidney function data review.

Pictet Asset Management Holding SA Cuts Stake in Vera Therapeutics, Inc. $VERA

Pictet Asset Management Holding SA cut its stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 3.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,392,421 shares of the company's stock after sellin...

Vera Therapeutics, Inc. is a clinical stage biotechnical company, which engages in the development and commercialization of transformative treatments for immunological diseases. Its product includes the TRUTAKNA injection. The company was founded by Marshall W. Fordyce in May 2016 and is headquartered in Brisbane, CA.

Vera Therapeutics Inc - Ordinary Shares - Class A

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$29.88
Prev Close	$29.73
Open	$29.57
Dividend Yield	0.00%
50-Day Moving Average	$32.67
Beta	1.30
Avg. Volume	2.53M
PE Ratio	-5.09

52-Week High	$56.05
52-Week Low	$23.05
Market Capitalization	$2.14B
EPS (Annual)	-$4.66
Price to Book	5.27
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

VERA Fundamentals